Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Reports of Practical Oncology and Radiotherapy
MENU
Shortcuts Special collections Ahead Of Print Submit an article Author Guidelines Reviewers 2022

open access

Vol 27, No 4 (2022)
Research paper
Published online: 2022-07-01
View PDF Download PDF file View HTML Supp./Additional Files [1]
Get Citation

Impact of COVID-19 on the curative treatment of prostate cancer: a national cross-sectional study

Andre Guimaraes Gouveia12, Fabio Ynoe Moraes32, Renato P. Lima4, Gustavo Viani52
DOI: 10.5603/RPOR.a2022.0070
·
Rep Pract Oncol Radiother 2022;27(4):659-665.
Affiliations
  1. Radiation Oncology Department, Americas Centro de Oncologia Integrado, Rio de Janeiro, Brazil
  2. Latin America Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
  3. Department of Oncology, Division of Radiation Oncology, Kingston General Hospital, Queen’s University, Kingston, ON, Canada, Kingston, Canada
  4. Radiation Oncology Department, Hospital Haroldo Juaçaba, Fortaleza, Ceará, Brazil
  5. Ribeirão Preto Medical School, Department of medical imagings, hematology and oncology of University of São Paulo (FMRP-USP), Ribeirão Pretol, Brazil

open access

Vol 27, No 4 (2022)
Original research articles
Published online: 2022-07-01

Abstract

Background: COVID-19 pandemic affected access to cancer treatment worldwide. However, there is a lack of data about the impact in developing countries.

The objective was to evaluate COVID-19 impact on curative prostate cancer (Pca) treatment in Brazil.

Materials and methods: With data extracted from the Brazilian Ministry of Health database, the Non-COVID and COVID periods were analyzed to compare the absolute number of radical prostatectomy (RP) and radiotherapy (RT) executed in the country and regions.

Results: With data from 50,169 Pca patients (NO COVID = 28,106 cases and COVID =22,063) treated with RP or RT in Brazil, a significant decline in patients receiving RT or RP (–6.043 cases; p = 0.0001) was detected. Both treatment procedures (RT or PR) were reduced in all five Brazilian regions comparing the Non-COVID and COVID periods. Overall, there was a reduction on RP and RT procedures in 92% (24/25) and 76% (19/25) of the evaluated states, respectively. Comparing the variation of RT and RP per state between COVID and Non-COVID period, there is a significant difference (–18.6% vs. –29%, p = 0.03) with a higher negative impact on the RP group. The RT and RP variation had no significant relationship with the incidence of COVID cases in the states. Limitations include the non-evaluation of treatment combinations, the impact of hypofractionated radiotherapy, and other factors influencing the treatment choice.

Conclusions: During the COVID-19 pandemic, the curative treatment with RP and RT of Pca was abruptly limited and affected. However, the number of RP was more impacted than RT during the COVID period.

 

Abstract

Background: COVID-19 pandemic affected access to cancer treatment worldwide. However, there is a lack of data about the impact in developing countries.

The objective was to evaluate COVID-19 impact on curative prostate cancer (Pca) treatment in Brazil.

Materials and methods: With data extracted from the Brazilian Ministry of Health database, the Non-COVID and COVID periods were analyzed to compare the absolute number of radical prostatectomy (RP) and radiotherapy (RT) executed in the country and regions.

Results: With data from 50,169 Pca patients (NO COVID = 28,106 cases and COVID =22,063) treated with RP or RT in Brazil, a significant decline in patients receiving RT or RP (–6.043 cases; p = 0.0001) was detected. Both treatment procedures (RT or PR) were reduced in all five Brazilian regions comparing the Non-COVID and COVID periods. Overall, there was a reduction on RP and RT procedures in 92% (24/25) and 76% (19/25) of the evaluated states, respectively. Comparing the variation of RT and RP per state between COVID and Non-COVID period, there is a significant difference (–18.6% vs. –29%, p = 0.03) with a higher negative impact on the RP group. The RT and RP variation had no significant relationship with the incidence of COVID cases in the states. Limitations include the non-evaluation of treatment combinations, the impact of hypofractionated radiotherapy, and other factors influencing the treatment choice.

Conclusions: During the COVID-19 pandemic, the curative treatment with RP and RT of Pca was abruptly limited and affected. However, the number of RP was more impacted than RT during the COVID period.

 

Full Text:

View PDF Download PDF file View HTML Supp./Additional Files [1]
Get Citation

Keywords

COVID-19; prostate cancer; radical prostatectomy; radiotherapy

Supp./Additional Files (1)
Supplementary File
Download
197KB
About this article
Title

Impact of COVID-19 on the curative treatment of prostate cancer: a national cross-sectional study

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 27, No 4 (2022)

Article type

Research paper

Pages

659-665

Published online

2022-07-01

Page views

2192

Article views/downloads

126

DOI

10.5603/RPOR.a2022.0070

Bibliographic record

Rep Pract Oncol Radiother 2022;27(4):659-665.

Keywords

COVID-19
prostate cancer
radical prostatectomy
radiotherapy

Authors

Andre Guimaraes Gouveia
Fabio Ynoe Moraes
Renato P. Lima
Gustavo Viani

References (24)
  1. Ministry of Health, Brazil — Covid incidence, cure, death and vaccination rates in Brazil. https://covid.saude.gov.br (1 November 2021).
  2. Asai Y, Nguyen P, Hanna TP. Impact of the COVID-19 pandemic on skin cancer diagnosis: A population-based study. PLoS One. 2021; 16(3): e0248492.
    CrossRefPubMed
  3. Spencer K, Jones CM, Girdler R, et al. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study. Lancet Oncol. 2021; 22(3): 309–320.
    CrossRefPubMed
  4. Eskander A, Li Q, Hallet J, et al. Access to Cancer Surgery in a Universal Health Care System During the COVID-19 Pandemic. JAMA Netw Open. 2021; 4(3): e211104.
    CrossRefPubMed
  5. Sud A, Jones ME, Broggio J, et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol. 2020; 31(8): 1065–1074.
    CrossRefPubMed
  6. Estimate 2020 – Cancer Incidence in Brazil. https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf. (1 November 2021).
  7. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017; 71(4): 618–629.
    CrossRefPubMed
  8. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004; 172(3): 910–914.
    CrossRefPubMed
  9. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001; 28(3): 555–565.
    CrossRefPubMed
  10. Baade PD, Dasgupta P, Aitken JF, et al. Distance to the closest radiotherapy facility and survival after a diagnosis of rectal cancer in Queensland. Med J Aust. 2011; 195(6): 350–354.
    CrossRefPubMed
  11. Collins IM, Lum C, Versace VL. Influence of socioeconomic factors and distance to radiotherapy on breast-conserving surgery rates for early breast cancer in regional Australia; implications of change. Asia Pac J Clin Oncol. 2018; 14(5): e224–e230.
    CrossRefPubMed
  12. Churilla TM, Donnelly PE, Leatherman ER, et al. Total Mastectomy or Breast Conservation Therapy? How Radiation Oncologist Accessibility Determines Treatment Choice and Quality: A SEER Data-base Analysis. Breast J. 2015; 21(5): 473–480.
    CrossRefPubMed
  13. Mahal BA, Chen YW, Sethi RV, et al. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. 2018; 124(6): 1141–1149.
    CrossRefPubMed
  14. Moraes FY, Marta GN, Hanna SA, et al. Brazil's Challenges and Opportunities. Int J Radiat Oncol Biol Phys. 2015; 92(4): 707–712.
    CrossRefPubMed
  15. Moraes FY, Mendez LC, Rosa AA, et al. Expanding Access to Radiation Therapy: An Update on Brazil's Current Challenges and Opportunities. Int J Radiat Oncol Biol Phys. 2018; 102(2): 463–464.
    CrossRefPubMed
  16. Mendez LC, Moraes FY, Fernandes GD, et al. Cancer Deaths due to Lack of Universal Access to Radiotherapy in the Brazilian Public Health System. Clin Oncol (R Coll Radiol). 2018; 30(1): e29–e36.
    CrossRefPubMed
  17. Atun R, Jaffray DA, Barton MB, et al. Expanding global access to radiotherapy. Lancet Oncol. 2015; 16(10): 1153–1186.
    CrossRefPubMed
  18. Hanna TP, Shafiq J, Delaney GP, et al. The population benefit of evidence-based radiotherapy: 5-Year local control and overall survival benefits. Radiother Oncol. 2018; 126(2): 191–197.
    CrossRefPubMed
  19. Ministry of Health, Brazil — Department of Informatics of the Unified Health System — SUS (DATASUS). https://datasus.saude.gov.br/informacoes-de-saude-tabnet/ 2003 (1 November 2021).
  20. Luizeti B, Perli V, Costa G, et al. Impact of the COVID-19 pandemic on surgical procedures in Brazil: a descriptive study. Iniciação Científica Cesumar. 2021; 23(2): 139–148.
    CrossRef
  21. Normando PG, Araujo-Filho Jd, Fonseca Gd, et al. Reduction in Hospitalization and Increase in Mortality Due to Cardiovascular Diseases during the COVID-19 Pandemic in Brazil. Arq Bras Cardiol. 2021; 116(3): 371–380.
    CrossRefPubMed
  22. Santos Filho A, Velasco W, Vieira L, Lima A. COVID-19: Suppressed demand for elective surgery - Subsecretary of Health — Strategic Information Management in Health — CONECTA-SUS. https://www.saude.go.gov.br/files//conecta-sus/produtos-tecnicos/I%20-%202021/COVID-19%20-%20Demanda%20reprimida%20de%20cirurgias%20eletivas.pdf.
  23. Dos Santos MB, Pires AL, Saporiti JM, et al. Impact of COVID-19 pandemic on oral health procedures provided by the Brazilian public health system: COVID-19 and oral health in Brazil. Health Policy Technol. 2021; 10(1): 135–142.
    CrossRefPubMed
  24. Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020; 371: m4087.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl